Newsroom – ARHP Commends FDA’s Recommendation to Approve Flibanserin

For Immediate Release
June 9,  2015

On Friday, a Food & Drug Administration (FDA) advisory committee voted 18-6 to recommend approval of flibanserin for the treatment of hypoactive sexual desire disorder in premenopausal women. Wayne Shields, ARHP President & CEO, presented comments to the committee in support of its approval and issued the following statement:

“On behalf of ARHP’s 12,000 health professional members, ARHP applauds the FDA’s approval of flibanserin, another option for women in the management of hypoactive sexual desire disorder (HSDD).

“ARHP serves as the voice of frontline sexual and reproductive health care providers in the United States and is committed to fostering evidence-based, patient-centered clinical care. ARHP is committed to ensuring that all people have access to and can make informed decisions about a variety of safe, effective treatment options that enhance quality of life and individual health outcomes. Women negatively impacted by HSDD deserve a wide range of beneficial treatment options, which, in addition to healthy diets, appropriate exercise, and psychotherapy and counseling, now includes a specific drug therapy option for HSDD.

“ARHP applauds the FDA’s due diligence during the application process and calls on the FDA to follow the recommendations of the advisory committee and approve the drug by its August 18 deadline.”


The Association of Reproductive Health Professionals (ARHP) is the leading source for trusted medical education and information on reproductive and sexual health. ARHP educates health care providers, informs consumers, and helps shape public policy. ARHP is a non-profit membership association composed of highly qualified and committed experts in reproductive health. ARHP members are health professionals in clinical practice, education, research, and advocacy and they include physicians, nurse practitioners, physician assistants, nurse midwives, researchers, educators, pharmacists, and other professionals in reproductive health. To learn more, visit: